IAV H1N1 HA blocking peptide

Name: IAV H1N1 HA blocking peptide
SKU: CDBP6216
Rating: 5 (1 reviews)

Synthetic IAV H1N1 HA blocking peptide for IB

COA

SDS

Datasheet

Summary

Nature

Synthetic

Tag/Conjugate

Unconjugated

Format

Liquid

Concentration

200 μg/mL

Preservative

None

Storage

-20°C

Introduction

H1N1 is subtype specie of Influenza A virus. H1N1 Influenza Virus has mutated into various strains such as the Spanish Flu strain, mild human flu strains, endemic pig strains, and various strains found in birds. The Influenza A Virus is a globular particle about 100nm in diameter, sheathed in a lipid bilayer derived from the plasma membrane of its host. Studded in the lipid bilayer are two integral membrane proteins some 500 molecules of hemagglutinin ("H") and some 100 molecules of neuraminidase ("N"). Within the lipid bilayer are 3000 molecules of matrix protein and 8 pieces of RNA. Each of the 8 RNA molecules is associated with many copies of a nucleoprotein, several molecules of the three subunits of its RNA polymerase some "non-structural" protein molecules of uncertain function.

Keywords

Orthomyxoviridae; Influenzavirus A; Influenza A virus; Influenza A virus H1N1 HA; H1N1 HA; H1N1; HA; Hemagglutinin; HA protein; HA1 protein; HA2 protein; Hemagglutinin protein; Influenza A Virus Hemagglutinin protein

Citations

Have you cited CDBP6216 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Global clinical trial mobilization for COVID-19: higher, faster, stronger

DRUG DISCOVERY TODAY

Authors: Beall, Reed F.; Hollis, Aidan

Abstract

The clinical trial landscape for Coronavirus 2019 (COVID-19) is radically different from that of previous epidemics. Compared with H1N1, Ebola, and Zika, COVID-19 had an order of magnitude more clinical trials within the first 3 months following the declaration of a Public Health Emergency of International Concern (PHEIC). These trials have started much faster, are more geographically diverse, and are less likely to be funded by industry. However, the almost simultaneous design and initiation of hundreds of trials with 0.3 million participants across 78 countries creates the potential for congestion and inefficiencies and enhances risks for investors. Thus, an international coordination mechanism for clinical trials could be valuable in this and other situations.

Design, synthesis and anti-influenza A virus activity of novel 2,4-disubstituted quinazoline derivatives

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Authors: Wang, Minghua; Zhang, Guoning; Wang, Yujia; Wang, Juxian; Zhu, Mei; Cen, Shan; Wang, Yucheng

Abstract

Four 2,4-disubstituted quinazoline series containing various amide moieties were designed and synthesized as new anti-influenza A virus agents using the strategies of bio-isosterism and scaffold hopping. Many of them exhibit potent in vitro anti-influenza A virus activity and low cytotoxicity (CC50: > 100 mu M). Particularly, compounds 10a5 and 17a show better activity (IC50: 3.70-4.19 mu M) and higher selective index (SI: > 27.03, > 23.87, respectively) against influenza A/WSN/33 virus (H1N1), opening a new direction for quinazoline derivatives in anti-influenza A virus field.